New Current Report Filed with the SEC Disclosing Receipt of a Notice of Delisting, the Failure to Satisfy a Continued Listing Rule or Standard or the Transfer of a Listing: 8-K – Tokai Pharmaceuticals Inc (0001404281) (Filer)

A current report on Form 8-K was just filed with the U.S. Securities & Exchange Commission (SEC) disclosing receipt of a notice of delisting, the failure to satisfy a continued listing rule or standard or the transfer of a listing. Details of the current report are:

8-K – Tokai Pharmaceuticals Inc (0001404281) (Filer)
Filed: 2017-03-09 AccNo: 0001193125-17-077021 Size: 15 KB

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Filing Date: 2017-03-09T17:00:56-05:00

This is a breaking news story. You can access the complete current report through the SEC’s Edgar system: http://www.sec.gov/Archives/edgar/data/1404281/000119312517077021/0001193125-17-077021-index.htm